期刊
CELL HOST & MICROBE
卷 29, 期 2, 页码 236-+出版社
CELL PRESS
DOI: 10.1016/j.chom.2020.12.010
关键词
-
资金
- European Union [653316, 665807]
- Institut Pasteur
- TheraVectys
- Agence Nationale de la Recherche HuMoCID
- Institut Carnot Pasteur Microbes Sante
- Marie Curie Actions (MSCA) [665807] Funding Source: Marie Curie Actions (MSCA)
Vaccination using a lentiviral vector to induce neutralizing antibodies against SARS-CoV-2 provides partial protection when administered systemically, but intranasal immunization results in a significant decrease in lung viral load and reduced local inflammation. Integrative and non-integrative lentiviral platforms both show strong vaccine efficacy against COVID-19 in golden hamsters, highlighting the potential of intranasal vaccination as a powerful approach.
To develop a vaccine candidate against coronavirus disease 2019 (COVID-19), we generated a lentiviral vector (LV) eliciting neutralizing antibodies against the Spike glycoprotein of SARS-CoV-2. Systemic vaccination by this vector in mice, in which the expression of the SARS-CoV-2 receptor hACE2 has been induced by transduction of respiratory tract cells by an adenoviral vector, confers only partial protection despite high levels of serum neutralizing activity. However, eliciting an immune response in the respiratory tract through an intranasal boost results in a >3 log(10) decrease in the lung viral loads and reduces local inflammation. Moreover, both integrative and non-integrative LV platforms display strong vaccine efficacy and inhibit lung deleterious injury in golden hamsters, which are naturally permissive to SARS-CoV-2 replication and closely mirror human COVID-19 physiopathology. Our results provide evidence of marked prophylactic effects of LV-based vaccination against SARS-CoV-2 and designate intranasal immunization as a powerful approach against COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据